$1.53 Billion is the total value of Bain Capital Life Sciences Investors, LLC's 30 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 16.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SWTX | SPRINGWORKS THERAPEUTICS INC | $480,558,000 | +12.0% | 5,831,307 | 0.0% | 31.49% | +29.6% | |
| AVIR | ATEA PHARMACEUTICALS, INC. | $120,624,000 | -65.2% | 5,615,659 | 0.0% | 7.90% | -59.8% | |
| DVAX | Buy | DYNAVAX TECHNOLOGIES CORP | $115,951,000 | +8.3% | 11,771,708 | +8.0% | 7.60% | +25.2% |
| DRNA | DICERNA PHARMACEUTICALS INC | $114,954,000 | +46.0% | 3,080,237 | 0.0% | 7.53% | +68.8% | |
| ARQT | ARCUTIS BIOTHERAPEUTICS INC. | $108,595,000 | -5.7% | 3,979,292 | 0.0% | 7.12% | +9.1% | |
| ANNX | ANNEXON INC | $72,969,000 | -19.1% | 3,241,628 | 0.0% | 4.78% | -6.5% | |
| CCCC | C4 THERAPEUTICS, INC. | $62,141,000 | +2.3% | 1,642,209 | 0.0% | 4.07% | +18.3% | |
| PHVS | PHARVARIS N.V. | $59,255,000 | -33.4% | 3,180,601 | 0.0% | 3.88% | -23.0% | |
| MRSN | MERSANA THERAPEUTICS INC. | $50,187,000 | -16.1% | 3,695,667 | 0.0% | 3.29% | -2.9% | |
| NRIX | NURIX THERAPEUTICS INC | $34,073,000 | -14.7% | 1,284,314 | 0.0% | 2.23% | -1.3% | |
| CRNX | Buy | CRINETICS PHARMACEUTICALS | $31,662,000 | +93.4% | 1,679,701 | +56.8% | 2.08% | +123.8% |
| SYRS | SYROS PHARMACEUTICALS INC. | $31,528,000 | -27.1% | 5,785,036 | 0.0% | 2.07% | -15.7% | |
| SLDB | SOLID BIOSCIENCES INC | $29,024,000 | -33.8% | 7,929,918 | 0.0% | 1.90% | -23.4% | |
| MARINUS PHARMACEUTICALS INC | $25,673,000 | +15.9% | 1,431,058 | 0.0% | 1.68% | +34.0% | ||
| APTX | APTINYX INC | $25,164,000 | -5.7% | 8,891,758 | 0.0% | 1.65% | +9.1% | |
| KYMR | KYMERA THERAPEUTICS INC. | $23,261,000 | +24.8% | 479,605 | 0.0% | 1.52% | +44.3% | |
| NAUT | New | NAUTILUS BIOTECHNOLOGY INC. | $20,200,000 | – | 2,000,000 | +100.0% | 1.32% | – |
| SVRA | SAVARA INC | $19,758,000 | -18.3% | 11,622,598 | 0.0% | 1.30% | -5.4% | |
| AGLE | AEGLEA BIO THERAPEUTICS INC | $18,792,000 | -12.1% | 2,700,000 | 0.0% | 1.23% | +1.7% | |
| BLUE | BLUEBIRD BIO, INC. | $17,211,000 | +6.1% | 538,179 | 0.0% | 1.13% | +22.7% | |
| XFOR | X4 PHARMACEUTICALS INC | $13,777,000 | -24.5% | 2,119,540 | 0.0% | 0.90% | -12.7% | |
| BCTG | Buy | BCTG ACQUISITION CORP | $10,490,000 | +88.7% | 921,790 | +84.4% | 0.69% | +118.1% |
| RACB | RESEARCH ALLIANCE CORP II | $10,140,000 | -1.1% | 1,000,000 | 0.0% | 0.66% | +14.3% | |
| ARYD | ARYA SCIENCES ACQU CORP IVcl a | $7,504,000 | +2.4% | 700,000 | 0.0% | 0.49% | +18.6% | |
| BLSA | BCLS ACQUISITION CORP | $5,133,000 | -0.4% | 487,500 | 0.0% | 0.34% | +15.1% | |
| PANA | New | PANACEA ACQUISITION CORP II | $5,010,000 | – | 500,000 | +100.0% | 0.33% | – |
| OMEG | OMEGA ALPHA SPACcl a | $3,980,000 | +0.5% | 400,000 | 0.0% | 0.26% | +16.5% | |
| FLACU | FRAZIER LIFESCIENCES ACQU COunit 12/09/2025 | $3,015,000 | -1.1% | 300,000 | 0.0% | 0.20% | +14.5% | |
| JYAC | JIYA ACQUISITION CORP | $2,982,000 | +1.0% | 300,000 | 0.0% | 0.20% | +16.8% | |
| HLXA | HELIX ACQUISITION CORP | $2,588,000 | +1.5% | 250,000 | 0.0% | 0.17% | +18.1% | |
| RACA | Exit | THERAPEUTICS ACQUISITION CORP | $0 | – | -1,000,000 | -100.0% | -0.60% | – |
| ARYA | Exit | ARYA SCIENCES ACQUISITION CORP III | $0 | – | -1,000,000 | -100.0% | -0.78% | – |
| CNST | Exit | CONSTELLATION PHARMACEUTICALS, INC. | $0 | – | -1,400,000 | -100.0% | -1.86% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Bain Capital Life Sciences Partners, LP #1
- Bain Capital Life Sciences Fund, L.P. #2
- BC SW, LP #3
- Bain Capital Life Sciences Investors II, LLC #4
- Bain Capital Life Sciences Fund II, L.P. #5
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-16
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| APTINYX INC | 20 | Q1 2023 | 16.9% |
| SOLID BIOSCIENCES INC | 19 | Q3 2022 | 22.2% |
| SPRINGWORKS THERAPEUTICS INC | 17 | Q3 2023 | 41.8% |
| DICERNA PHARMACEUTICALS INC | 16 | Q3 2021 | 58.6% |
| DYNAVAX TECHNOLOGIES CORP. | 16 | Q3 2023 | 12.4% |
| SAVARA INC | 16 | Q3 2023 | 6.0% |
| X4 PHARMACEUTICALS INC | 16 | Q3 2023 | 3.2% |
| ARCUTIS BIOTHERAPEUTICS, INC. | 15 | Q3 2023 | 20.1% |
| MERSANA THERAPEUTICS, INC. | 14 | Q3 2023 | 8.4% |
| CRINETICS PHARMACEUTICALS, INC. | 14 | Q3 2023 | 5.4% |
View Bain Capital Life Sciences Investors, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-02-14 |
| 13F-HR | 2024-02-13 |
| 3 | 2024-02-07 |
| 4 | 2024-01-12 |
| 3 | 2023-12-29 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 3 | 2023-05-30 |
| 4 | 2023-05-30 |
| 13F-HR | 2023-05-15 |
View Bain Capital Life Sciences Investors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.